CHINESE JOURNAL OF MEDICINAL GUIDE >
Clinical Study of Acetylcysteine Injection to Improve Liver and Kidney Function in Patients with Heart Failure and Renal Insufficiency
Received date: 2025-05-05
Revised date: 2025-08-04
Accepted date: 2026-02-06
Online published: 2026-04-21
Objective： To observe the effects of acetylcysteine injection on cardiac， hepatic， and renal function in patients with heart failure accompanied by renal insufli ciency.Methods： A total of 140 patients with cardiorenal comorbidities admitted from January 2017 to June 2023 were enrolled， and the study subjects were divided into the control group （n=70， conventional treatment） and the observation group （n=70， conventional treatment plus acetylcysteine injection） according to the treatment plan. Cardiac function indexes， liver and kidney function indexes and echocardiography parameters were compared between the two groups at baseline and after treatment.Results： Following therapy， NT-proBNP concentrations decreased significantly in both cohorts relative to pretreatment values （P<0.05）. Pretreatment estimated glomerular filtration rate （eGFR） did not differ between groups （P>0.05）. However， after treatment， the observation group had significantly higher eGFR compared to the control group （P<0.05） and showed a significant rise from pre-intervention measurements （P<0.05）. In addition， after treatment， serum creatinine （Scr）， blood urea nitrogen（BUN）， and uric acid （UA） in the observation group were markedly reduced （P<0.05）， all were markedly below in the control group （P<0.05）. After treatment， both groups showed significant reductions in alanine aminotransferase （ALT） and aspartate aminotransferase （AST） （P<0.05）. Post-intervention analysis revealed significantly reduced ALT and AST levels in the observation group compared to the control group （P<0.05）. Following therapy， before treatment， the LVDD of patients in the observation group was lower than that of the control group （P<0.05）， while there were no statistically significant differences in LAD， IVSD， and LVEF levels between the two groups （P>0.05）. After treatment， the LAD of the observation group decreased compared to pre-treatment （P<0.05）， but no significant differences were observed in LVDD， IVSD， and LVEF between the two groups compared to pre-treatment （P>0.05）.Conclusion： Acetylcysteine injection can improve liver and renal function in patients with heart failure combined with renal insufficiency and reduce the LAD. However， it has no significant short-term impact on cardiac function parameters such as LVEF and LVDD.
Ze-Yang LIN
.
Clinical Study of Acetylcysteine Injection to
Improve Liver and Kidney Function in Patients with Heart Failure and Renal
Insufficiency
［1］ Task Force Members，McDonagh TA， Metra M， et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure： developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology （ESC）. With the special contribution of the Heart Failure Association （HFA） of the ESC［J］.Eur J Heart Fail， 2022，24（1）：4-131.
［2］ Piano MR， Kim SD， Jarvis C. Cellular Events linked to cardiac remodeling in heart failure： targets for pharmacologic intervention［J］.J Cardiovasc Nurs， 2000，14（4）：1-23，119-120.
［3］ Pouleur AC. Which biomarkers do clinicians need for diagnosis and management of heart failure with reduced ejection fraction［J］.Clinica Chimica Acta， 2015，443：9-16.
［4］ Chiu AH， Wang CJ， Lin YL， et al. N-acetylcysteine alleviates the progression of chronic kidney disease： a three-year cohort study［J］.Medicina， 2023， 59（11）：1983.
［5］ van der Aart-van der Beek AB， de Boer RA， Heerspink HJL. Kidney and heart failure outcomes associated with SGLT2 inhibitor use［J］.Nat Rev Nephrol， 2022，18（5）：294-306.
［6］ Ruilope LM， Segura J. Cardiovascular therapy in patients with renal insufficiency［J］.Cardiovasc Drug Ther， 2002，16（6）：497-501.
［7］ Schefold JC， Filippatos G， Hasenfuss G， et al. Heart failure and kidney dysfunction： epidemiology， mechanisms and management［J］.Nat Rev Nephrol， 2016，12（10）：610-623.
［8］ Javaherforooshzadeh F， Shaker Z， Rashidi M， et al. The effect of N-acetyl cysteine injection on renal function after coronary artery bypass graft surgery： a randomized double blind clinical trial［J］.J Cardiothorac Surg， 2021，16（1）：161.
［9］ Moreira MA， Irigoyen MC， Saad KR， et al. N-acetylcysteine reduces the renal oxidative stress and apoptosis induced by hemorrhagic shock［J］.J Surg Res， 2016，203（1）：113-120.
［10］ Fang X， Liu L， Zhou S， et al. N‑acetylcysteine inhibits atherosclerosis by correcting glutathione‑dependent methylglyoxal elimination and dicarbonyl/oxidative stress in the aorta of diabetic mice［J］.Mol Med Rep， 2021，23（3）：1-9.
［11］ Smaga I， Frankowska M， Filip M. N‐acetylcysteine as a new prominent approach for treating psychiatric disorders［J］.Br J Pharmacol， 2021，178（13）：2569-2594.
［12］ Jegatheeswaran S， Siriwardena AK. Experimental and clinical evidence for modification of hepatic ischaemia-reperfusion injury by N-acetylcysteine during major liver surgery［J］.Hpb， 2011，13（2）：71-78.
［13］ Ramachandran A， Akakpo JY， Curry SC， et al. Clinically relevant therapeutic approaches against acetaminophen hepatotoxicity and acute liver failure［J］.Biochem Pharmacol， 2024，228：1-10.
［14］ Efrati S， Averbukh M， Berman S， et al. N-Acetylcysteine ameliorates lithium-induced renal failure in rats［J］.Nephrol Dial Transplant， 2005，20（1）：65-70.
［15］ 马璟婷，宋沧桑，李兴德，等.药物性肝损伤发生机制的研究进展［J］.中国药物评价，2024，41（2）：132-135.
［16］ Stevens PE， Ahmed SB， Carrero JJ， et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease［J］.Kidney Int， 2024，105（4）：S117-S314.
［17］ Beldhuis IE， Lam CSP， Testani JM， et al. Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease［J］.Circulation， 2022，145（9）：693-712.
［18］ Tang WHW， Francis GS. The year in heart failure［J］.J Am Coll Cardiol， 2007， 50（24）： 2344-2351.
［19］ Wang Y， Zhao S， Chen Y， et al. N-Acetyl cysteine effectively alleviates coxsackievirus B-induced myocarditis through suppressing viral replication and inflammatory response［J］.Antiviral Res， 2020，179：104699.
［20］ Cepaityte D， Leivaditis K， Varouktsi G， et al. N-acetylcysteine： more than preventing contrast-induced nephropathy in uremic patients—focus on the antioxidant and anti-inflammatory properties［J］.Int Urol Nephrol， 2023，55（6）：1481-1492.
［21］ Zaki SM， Abdalla IL， Sadik AOE， et al. Protective role of N-acetylcysteine on isoprenaline-induced myocardial injury： histological， immunohistochemical and morphometric study［J］.Cardiovasc Toxicol， 2017，18（1）：9-23.
［22］ Erbas H， Aydogdu N， Kaymak K. Effects of N-acetylcysteine on arginase， ornithine and nitric oxide in renal ischemia-reperfusion injury［J］.Pharmacol Res， 2004，50（5）：523-527.
［23］ Higuchi Y， Otsu K， Nishida K， et al. Involvement of reactive oxygen species-mediated NF-κ activation in TNF-α-induced cardiomyocyte hypertrophy［J］.J Mol Cell Cardiol， 2002，34（2）：233-240.
［24］ Niwano S， Niwano H， Sasaki S， et al. N-acetylcysteine suppresses the progression of ventricular remodeling in acute myocarditis： studies in an experimental autoimmune myocarditis （EAM） model［J］.Circ J， 2011，75（3）：662-671.
［25］ Liu C， Lu XZ， Shen MZ， et al. N-acetyl cysteine improves the diabetic cardiac function： possible role of fibrosis inhibition［J］.BMC Cardiovasc Disord， 2015，15：84.
［26］ Martinez de Lizarrondo S， Gakuba C， Herbig B A， et al. Potent thrombolytic effect of N-acetylcysteine on arterial thrombi［J］.Circulation， 2017，136（7）：646-660.
/
| 〈 |
|
〉 |